Glembatumumab vedotin
Based on 2 publication(s) in Google Scholar
Glembatumumab vedotin (CDX-011) is an ADC comprising a fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB) and conjugated to the potent tubulinbinding cytotoxic agent MMAE via a protease-sensitive vc linker. Glembatumumab vedotin has potent anticancer effects.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: ≥99.0%
- No. CAS: 1182215-65-1
- Peso molecular:150000 (average)
-
Almacenamiento:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-152963
Tisotumab vedotin
-
HY-138298A
Trastuzumab deruxtecan
-
HY-141601
Telisotuzumab vedotin
-
HY-P9985
Disitamab vedotin
-
HY-132253
Polatuzumab vedotin
-
HY-132254
Sacituzumab govitecan
-
HY-P99813
Patritumab deruxtecan
-
HY-P3239
Belantamab mafodotin
-
HY-P99612
Farletuzumab ecteribulin
-
HY-P99829
Cofetuzumab pelidotin
-
HY-P99205
Glembatumumab
-
HY-P99547
Trastuzumab duocarmazine
Publications Citing Use of MedChemExpress (MCE) Glembatumumab vedotin
More
Actividad biológica
Glembatumumab vedotin binds to GPNMB on tumors, the complex is internalized and MMAE is released via proteolytic cleavage of the vc linker in a lysosomal compartment. Tumor cell death occurs as a result of microtubule inhibition by MMAE with resultant cell cycle arrest[1].
Glembatumumab vedotin (1-125 μg/mL; 96 hours) demonstrates osteosarcoma cytotoxic activity[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Osteosarcoma cell lines
-
Concentration:1 μg/mL to 125 μg/mL
-
Incubation Time:96 hours
-
Result:Demonstrated osteosarcoma cytotoxic activity.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Athymic mice (6-week-old) injected with human SK-MEL-2 and SK-MEL-5 melanoma cells[2]
-
Dosage:1.25 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg, 60 mg/kg, 80 mg/kg
-
Administration:i.v.; every 4 days; for 16 days
-
Result:Showed inhibition of tumor growth.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 1182215-65-1
-
Appearance Liquid
-
Peso molecular 150000 (average)
-
Color Colorless to light yellow
-
SMILES
[Glembatumumab vedotin]
-
Synonyms
CDX-011; CR011-vcMMAE
-
Envío
Shipping with dry ice.
-
Almacenamiento
-80°C, protect from light
Publications (2)
-
Journal Impact Factor
-
Most Recent
Pureza y Documentación
-
Ficha de datos (269 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Christopher H Keir, et al. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther. 2012 Feb;12(2):259-63. [Content Brief]
[2]. Vincent A Pollack, et al. Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB. Cancer Chemother Pharmacol. 2007 Aug;60(3):423-35. [Content Brief]
[3]. Michael Roth, et al. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma. Pediatr Blood Cancer. 2016 Jan;63(1):32-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Glembatumumab vedotin Related Classifications
HY-141604 Related Classifications
Powered by Bioz